The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients

Blood

Volumn 120, Issue 13, 2012, Pages 2690-2699

  Mans, Sarah ^a   Banz, Yara ^a   Mueller, Beatrice U ^a   Pabst, Thomas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; CALRETICULIN; DOXORUBICIN; LEUKOCYTE ELASTASE; UNCLASSIFIED DRUG; VASOSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SURFACE; CONTROLLED STUDY; DISEASE COURSE; EXOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 84866852897     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-412759     Document Type: Article

References (40)

1. Zhang DE, Zhang P, Wang ND, et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A. 1997;94(2):569-574. (Pubitemid 27053674)
2. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003;3(2):89-101. (Pubitemid 37328876)
3. Pabst T, Mueller BU, Zhang P, et al. Dominantnegative mutations of CEBPA, encoding CCAAT/ enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3): 263-270. (Pubitemid 32201846)
4. Haefliger S, Klebig C, Schaubitzer K, et al. Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Blood. 2011;117(22):5931-5940.
5. Kim R, Emi M, Tanabe K, et al. Role of the unfolded protein response in cell death. Apoptosis. 2006;11(1):5-13. (Pubitemid 43151639)
6. Michalak M, Corbett EF, Mesaeli N, et al. Calreticulin: one protein, one gene, many functions. Biochem J. 1999;344(2):281-292. (Pubitemid 30011581)
7. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61. (Pubitemid 46067386)
8. Obeid M, Panaretakis T, Tesniere A, et al. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res. 2007;67(17):7941-7944. (Pubitemid 47395121)
9. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009; 28(5):578-590.
10. Eggleton P, Ward FJ, Johnson S, et al. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization. Clin Exp Immunol. 2000;120(2):384-391. (Pubitemid 30304238)
11. Schardt JA, Weber D, Eyholzer M, et al. Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res. 2009;15(11):3834-3841.
12. Yoshida H. Unconventional splicing of XBP-1 mRNA in the unfolded protein response. Antioxid Redox Signal. 2007;9(12):2323-2333. (Pubitemid 350059021)
13. Schardt JA, Eyholzer M, Timchenko NA, et al. Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukemia. J Cell Mol Med. 2010;14(6b):1509-1519.
14. Michalak M, Milner RE, Burns K, et al. Calreticulin. Biochem J. 1992;285(3):681-692.
15. Klausner RD, Donaldson JG, Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol. 1992; 116(5):1071-1080.
16. Johnson S, Michalak M, Opas M, et al. The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol. 2001;11(3): 122-129. (Pubitemid 32289442)
17. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6(7):541-550. (Pubitemid 43980526)
18. Rawlings ND. A large and accurate collection of peptidase cleavages in the MEROPS database. Database (Oxford). 2009:bap015.
19. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the peptidase database. Nucleic Acids Res. 2010; 38(Database issue):227-233.
20. Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med. 1998; 188(12):2349-2356. (Pubitemid 29028507)
21. Tavor S, Petit I, Porozov S, et al. Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood. 2005;106(6):2120-2127. (Pubitemid 41291729)
22. Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood. 1999; 94(7):2461-2468. (Pubitemid 29467695)
23. Persano L, Crescenzi M, Indraccolo S. Antiangiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med. 2007; 28(1):87-114.
24. Cai KX, Tse LY, Leung C, et al. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin Cancer Res. 2008;14(3):939-949. (Pubitemid 351232942)
25. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2001;106(4):170-176. (Pubitemid 34124156)
26. Gold LI, Eggleton P, Sweetwyne MT, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2010;24(3): 665-683.
27. Gardai SJ, McPhillips KA, Frasch SC, et al. Cellsurface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321-334. (Pubitemid 41457220)
28. Wemeau M, Kepp O, Tesniere A, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010; 1(2):e104.
29. Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008;15(9):1499-1509.
30. Gotoh T, Oyadomari S, Mori K, et al. Nitric oxideinduced apoptosis in RAW 264.7 macrophages is mediated by endoplasmic reticulum stress pathway involving ATF6 and CHOP. J Biol Chem. 2002;277(14):12343-12350. (Pubitemid 34952805)
31. Kim YH, Joo HS, Kim DS. Nitric oxide induction of IRE1-alpha-dependent CREB phosphorylation in human glioma cells. Nitric Oxide. 2010;23(2):112-120.
32. De Boo S, Kopecka J, Brusa D, et al. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer. 2009;8(19):108-111.
33. Shellard JE, Leitch HA, Logan PM, et al. Purification of an in vitro inhibitor of normal myelopoiesis using a monoclonal antibody directed to a common antigen of myelogenous leukemia (CAMAL). Exp Hematol. 1991;19(2):136-142.
34. Lausen J, Liu S, Fliegauf M, et al. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO. Oncogene. 2006; 25(9):1349-1357. (Pubitemid 43336463)
35. Corbett EF, Michalak KM, Oikawa K, et al. The conformation of calreticulin is influenced by the endoplasmic reticulum luminal environment. J Biol Chem. 2000;275(35):27177-27185.
36. Trujillo A, McGee C, Cogle CR. Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol. 2012;2012(12608): 1286-1294.
37. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95(1):309-313. (Pubitemid 30017257)
38. Shago M, Flock G, Leung Hagesteijn CY, et al. Modulation of the retinoic acid and retinoid X receptor signaling pathways in P19 embryonal carcinoma cells by calreticulin. Exp Cell Res. 1997; 230(1):50-60. (Pubitemid 27187539)
39. Ghannadan M, Wimazal F, Simonitsch I, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol. 2003; 119(5):663-671. (Pubitemid 37046387)
40. Teng CL, Young JH, Hsu SL, et al. Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia. J Chin Med Assoc. 2006;69(11):534-537.